JPRN-UMIN000002439
Completed
未知
Clinical study on revaccination with pneumococcal polysaccharide vaccine. -Safety and immunogenicity of revaccination - - Clinical study on revaccination with pneumococcal polysaccharide vaccine. -Safety and immunogenicity of revaccination
ational Hospital Organization, Tokyo National Hospital0 sites80 target enrollmentSeptember 3, 2009
ConditionsChronic lung disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic lung disease
- Sponsor
- ational Hospital Organization, Tokyo National Hospital
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients under treatment of radiotherapy and immunosuppressant at present and/or soon after revaccination. 2\) Patients who have fever obviously. 3\) Patients who have serious acute diseases obviously. 4\) Patients who have ever showed anaphylaxis due to ingredient(s) of this vaccine. 5\) Patients who are not appropriate to be vaccinated for other reasons.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Revaccination with Pneumococcal Conjugate Vaccine - Characterization of the Immune Response after Polysaccharide (REPLAY) - REPLAYInvasive pneumococcal diseaseMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2008-006194-33-ISWyeth Research Division of Wyeth Pharmaceuticals Inc.224
Active, not recruiting
Not Applicable
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled TrialThe primary objectives of this study are to:1.Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one year period.2.Evaluate whether a strategy combining a prime with the 13-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the PPV23 would improve immunogenicity against Streptococcus Pneumoniae Polysaccharides (SPP) in HIV-infected patients.EUCTR2011-000260-99-IEDepartment of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8150
Not yet recruiting
Not Applicable
Efficacy of pneumococcal conjugate vaccine in preventing acquisition and carriage of pneumococcal vaccine serotypes in Tanzanian children with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS)Pneumococcal diseaseHIV/AIDSPublic Health - EpidemiologyInfection - Studies of infection and infectious agentsACTRN12610000999033Prof Robert Booy216
Active, not recruiting
Not Applicable
The role of under-fives in pneumococcal transmission to newborn babies within householdsISRCTN10912262iverpool School of Tropical Medicine2,588
Active, not recruiting
Phase 1
Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligneEUCTR2019-002542-20-FRCHRU de TOURS36